Michael A. Bookman, MD graduated from the Massachusetts Institute of Technology and Harvard Medical School, followed by residency training at Beth Israel Hospital in Boston. In 1988, after completing a senior staff fellowship within the Medicine Branch of the National Cancer Institute, he joined the Department of Medical Oncology at Fox Chase Cancer Center in Philadelphia PA, where he remained for 21 years, most recently as Vice President for Ambulatory Care and Clinical Research. In September 2009, Michael joined the University of Arizona Cancer Center in Tucson as Professor of Medicine and Division Chief for Hematology-Oncology. In October 2014, he joined US Oncology Research (McKesson Specialty Health) as Director for Gynecologic Oncology Research, and joined Arizona Oncology in Tucson to pursue a multidisciplinary practice in gynecologic oncology.
For more than 20 years, he has worked closely with the Gynecologic Oncology Group (GOG) to support clinical research for women with gynecologic cancers, and mentorship for junior investigators. His roles have included Chair of the Developmental Therapeutics Committee and the Committee on Information Technology. He has served as Chair of the Ovarian Committee since August 2010, including transition to NRG Oncology as part of the NCI National Clinical Trials Network. In addition, he served as Principal Investigator for GOG0182-ICON5, an international collaborative phase III trial for women with advanced ovarian cancer, which enrolled over 4,000 patients to evaluate new chemotherapy treatment combinations.
In July 2006, Dr. Bookman was appointed Director, Office of Educational Resources of the International Gynecologic Cancer Society (IGCS), continuing through 2016. This offered a unique opportunity to focus on the development of resources to support global and regional educational initiatives of the Society, targeting healthcare providers and patients in diverse international settings.
Within the National Comprehensive Cancer Network (NCCN), Dr. Bookman served as a member of the Outcomes Committee, and was a co-investigator for the breast cancer and ovarian cancer outcomes database projects, as well as a member of the Guidelines Committee for cancer of the uterus and cervix.